Nadroparin Calcium
drugOn this page
Also known as CY 216CY-216FraxiparinFraxiparinaFraxiparineNadroparinNadroparina calcicaNadroparine calciqueSeleparinaUltraparinaNADROPARINE
Summary
Nadroparin Calcium (CHEMBL2109204) is an approved oligosaccharide (ATC B01AB06); indicated across 7 conditions including thrombotic disease and venous thromboembolism.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Oligosaccharide
- ATC class: B01AB06
- Indications: 7 conditions
- Clinical trials: 24
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109204 |
| Name | Nadroparin Calcium |
| Type | Oligosaccharide |
| Max phase | 4 |
| ATC | B01AB06 |
Also known as: CY 216, CY-216, Fraxiparin, Fraxiparina, Fraxiparine, Nadroparin, Nadroparin calcium, Nadroparina calcica, Nadroparine calcique, Seleparina, Ultraparina, NADROPARINE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| thrombotic disease | 3 | MONDO:0000831 | HP:0004419 |
| venous thromboembolism | 3 | MONDO:0005399 | EFO:0004286 |
| thrombophilia | 3 | MONDO:0002305 | EFO:0009315 |
| lung neoplasm | 3 | MONDO:0021117 | MONDO:0008903 |
| neoplasm | 3 | MONDO:0005070 | MONDO:0004992 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 24.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 9 |
| PHASE4 | 8 |
| Not specified | 6 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00286273 | PHASE4 | COMPLETED | Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration |
| NCT00796692 | PHASE4 | COMPLETED | Nadroparin for the Initial Treatment of Pulmonary Thromboembolism |
| NCT01862978 | PHASE4 | UNKNOWN | Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke |
| NCT02295150 | PHASE4 | UNKNOWN | Prophylaxis of Venous Thromboembolism After Bariatric Surgery |
| NCT02398357 | PHASE4 | UNKNOWN | The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis |
| NCT02630095 | PHASE4 | UNKNOWN | The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT |
| NCT02957877 | PHASE4 | UNKNOWN | LMWH Infusion as Anticoagulation for Home HD |
| NCT04173429 | PHASE4 | COMPLETED | Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis |
| NCT00312013 | PHASE3 | COMPLETED | Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer |
| NCT00421538 | PHASE3 | COMPLETED | Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT) |
| NCT00843492 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery |
| NCT00881088 | PHASE2/PHASE3 | UNKNOWN | Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures |
| NCT00951574 | PHASE3 | COMPLETED | Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium) |
| NCT01019655 | PHASE3 | UNKNOWN | Heparin for Pregnant Women With Thrombophilia |
| NCT01431456 | PHASE3 | COMPLETED | Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery |
| NCT01980849 | PHASE3 | UNKNOWN | Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer |
| NCT04066764 | PHASE3 | UNKNOWN | Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters |
| NCT04067505 | PHASE3 | UNKNOWN | Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study |
| NCT06319131 | Not specified | NOT_YET_RECRUITING | Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT |
| NCT00303407 | Not specified | TERMINATED | Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care |
| NCT01267305 | Not specified | COMPLETED | The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery |
| NCT02526303 | Not specified | WITHDRAWN | Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis |
| NCT02987946 | Not specified | COMPLETED | Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events |
| NCT05621915 | Not specified | COMPLETED | Nadroparin Pharmacokinetics in Different Stages of COVID-19 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).